Catheter Precision to Attend and Participate in the Western Atrial Fibrillation Symposium
Rhea-AI Summary
Catheter Precision (NYSE/American: VTAK) has announced its participation in the 18th Western Atrial Fibrillation Symposium from February 27 – March 1 in Salt Lake City, Utah. The symposium, featuring over 80 world-renowned faculty members, focuses on improving atrial fibrillation (AF) outcomes globally through discussions of latest diagnostic and treatment advancements.
The company aims to showcase its LockeT product line, which serves as an adjunctive solution for atrial fibrillation procedures. CEO David Jenkins emphasized that attending industry-specific meetings is important to their commercialization strategy, with the goal of educating physicians about LockeT's benefits for recovery room staff, hospitals, and patients.
Positive
- None.
Negative
- None.
News Market Reaction – VTAK
On the day this news was published, VTAK gained 1.28%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
FORT MILL, S.C., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device company focused on developing technologically advanced products for the cardiac electrophysiology market announced their attendance at the 18th Western Atrial Fibrillation Symposium from February 27 – March 1 in Salt Lake City, Utah.
Western AF is an internationally recognized meeting focused on improving atrial fibrillation (AF) outcomes worldwide. Led by more than 80 world-renowned faculty who will discuss the latest advancements in diagnosis and treatment, the program includes challenging case studies, engaging panel discussions, and topic-focused roundtables for interactive learning.
David Jenkins, CEO of Catheter Precision, said, “Attendance at industry specific meetings is part of our commercialization strategy. Western AF is well attended by leading experts in the field of atrial ablation and our LockeT product line is an attractive adjunctive piece for the atrial fibrillation procedure. Our hope is to introduce and educate physicians on LockeT and the many benefits it can provide their recovery room staff, the hospital, and most importantly, the patients.”
About LockeT
Catheter Precision’s LockeT is a suture retention device intended to assist in hemostasis after vascular catheter access. LockeT is a Class 1 device registered with the FDA.
About Catheter Precision
Catheter Precision is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.
Cautionary Note Regarding Forward-Looking Statements
Statements in this press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to substantial risk and uncertainties. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words. These forward-looking statements include, but are not limited to, statements regarding product evaluations at the hospital, and that the purchase order indicates that the hospital and its staff see the value and benefits that LockeT can bring and expectations regarding LockeT evaluations in the coming weeks. The Company’s expectations and beliefs regarding these matters may not materialize. Actual outcomes and results may differ materially from those contemplated by these forward-looking statements as a result of uncertainties, risks and changes in circumstances, including but not limited to risks and uncertainties included under the caption “Risk Factors” in the Company’s Form 10-K filed with the SEC and available at www.sec.gov.
The forward-looking statements included in this communication are made only as of the date hereof. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
CONTACTS:
At the Company
David Jenkins
973-691-2000
info@catheterprecision.com
# # #
FAQ
What is the significance of Catheter Precision (VTAK) attending the Western AF Symposium 2025?
When and where is the 18th Western Atrial Fibrillation Symposium taking place?
What is the focus of VTAK's LockeT product line presentation at the Western AF Symposium?
How many faculty members are participating in the 2025 Western AF Symposium?
What educational formats are included in the Western AF Symposium 2025?
